Immunotolerance in Endometrial Cancer and at the Maternal-fetal Interface: Immunological Profiling of the Tumor Microenvironment in Risk Stratification of Recurrence

RecruitingOBSERVATIONAL
Enrollment

30

Participants

Timeline

Start Date

December 13, 2022

Primary Completion Date

December 13, 2025

Study Completion Date

December 13, 2025

Conditions
Endometrial Cancer
Interventions
DIAGNOSTIC_TEST

tissue samples (healthy and tumor taken from the same patient) and tissue samples (decidualized endometrium and trophoblast taken from it patient)

Correlation between the immuno-score results of each patient with his prognosis, in terms disease-free survival, overall survival, relapse-free survival, disease-specific survival cancer, distant and/or local free survival, to validate their potential role independent in the progression of endometrial cancer; later, for a better characterization of the various ones risk classes, we will combine our immuno-score with the already known risk factors, included in the ESMO-ESGO-ESTRO classification and in the biomolecular classification of endometrial cancer, to investigate whether the Microenvironmental immunological factors in endometrial cancer could allow better stratification of patients in risk classes.

Trial Locations (1)

00144

RECRUITING

"Regina Elena National Cancer Institute", Rome

All Listed Sponsors
collaborator

Federico II University

OTHER

lead

Regina Elena Cancer Institute

OTHER